Total
0
Shares
Pharmadrug to acquire psychedelics company
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Lobe Sciences (LOBE) has been added to the Horizons Psychedelic Stock Index ETF (PSYK)
  • The company has also been added to its underlying index, the Horizons North American Psychedelics Index
  • PSYK is an ETF which seeks to replicate the performance of the Index
  • The Index rebalances each calendar quarter
  • Lobe is a life sciences company focused on psychedelic medicines
  • Lobe Sciences is up 2.94 per cent on the day, with shares trading at C$0.18 at 2:17 pm ET

Lobe Sciences (LOBE) has been added to the Horizons Psychedelic Stock Index ETF (PSYK).

The company has also been added to its underlying index, the Horizons North American Psychedelics Index.

PSYK is an ETF which seeks to replicate, to the extent possible, the performance of the Horizons Psychedelic Stock Index.

The Index is a proprietary index owned and operated by Horizons ETFs, and Solactive AG is the independent calculation agent.

The Index rebalances each calendar quarter.

It has been designed to provide a measure of the performance of North American publicly-listed life sciences companies focused on psychedelic medicines, and other companies with business activities in the psychedelics industry.

"We are pleased to have been added to the ETF and Index, and look forward to the added market exposure this will bring the Company. Lobe continues to pursue its objectives for the development of psychedelics to improve mental health and wellness," said Lobe CEO and Director Philip Young.

Lobe is a life sciences company focused on psychedelic medicines.

Through collaborations with industry leading partners, the company is engaged in drug research and development using psychedelic compounds and the development of innovative devices and delivery mechanisms to improve mental health and wellness.

Lobe Sciences is up 2.94 per cent on the day, with shares trading at C$0.18 at 2:17 pm ET.

More From The Market Herald
Psyence Group (CSE:PSYG) and Pure Extracts (CSE:PULL) form psychedelics joint venture

" Psyence Group (CSE:PSYG) and Pure Extracts (CSE:PULL) form psychedelics joint venture

Pure Extracts (PULL) and Psyence Group (PSYG) have formed a JV for psychedelic medicinal mushroom extracts.
Levitee Labs - CEO, Pouya Farmand. - The Market Herald Canada

" Levitee Labs (CSE:LVT) announces DTC eligibility

Common shares of Levitee Labs (LVT) are now eligible to be electronically cleared and settled through the DTC.
Mindset Pharma (CSE:MSET) announces inclusion in the AdvisorShares Psychedelics Exchange Traded Fund

" Mindset Pharma (CSE:MSET) announces inclusion in the AdvisorShares Psychedelics Exchange Traded Fund

Mindset Pharma (MSET) has announced its inclusion in the NYSE-traded AdvisorShares Psychedelics ETF.
Clearmind Medicine (CSE:CMND) announces closing of private placement

" Clearmind Medicine (CSE:CMND) partners with The Hebrew University

Clearmind Medicine (CMND) has established a research and development partnership with the Yissum Research Development Company.